{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:22:07Z","timestamp":1791123727371,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5,27]]},"DOI":"10.1097\/tp.0b013e3181d75952","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T05:40:39Z","timestamp":1268890839000},"page":"1255-1262","source":"Crossref","is-referenced-by-count":18,"title":["Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial"],"prefix":"10.1097","volume":"89","author":[{"given":"Annick","family":"Rousseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Venisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Loichot-Roselmac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Turcant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Hoizey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Compagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Hary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00e8le","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Saivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Jacqz-Aigrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Vergnen\u00e8gre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1097\/01.tp.0000186380.61251.fc","article-title":"The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation.","volume":"80","author":"van Gelder","year":"2005","journal-title":"Transplantation"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1034\/j.1399-0012.2001.150607.x","article-title":"Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients.","volume":"15","author":"Cattaneo","year":"2001","journal-title":"Clin Transplant"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s004670050021","article-title":"Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.","volume":"14","author":"Filler","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/0091270004270145","article-title":"Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients.","volume":"45","author":"Pisupati","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1345\/aph.1E287","article-title":"Immunosuppressant drug monitoring: Is the lab oratory meeting clinical expectations?","volume":"39","author":"Morris","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/01.tp.0000232697.38021.9a","article-title":"Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: Review of the literature.","volume":"82","author":"Arns","year":"2006","journal-title":"Transplantation"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0b013e3181744199","article-title":"Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review.","volume":"85","author":"Knight","year":"2008","journal-title":"Transplantation"},{"key":"R8-12-20210129","first-page":"1","article-title":"Utility of monitoring mycophenolic acid in solid organ transplant patients.","volume":"164","author":"Oremus","year":"2008","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200108000-00001","article-title":"Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion.","volume":"23","author":"Shaw","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":"Therapeutic drug monitoring of mycophenolate mofetil in transplantation.","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2710.2006.00713.x","article-title":"Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.","volume":"31","author":"Pawinski","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00007691-200010000-00008","article-title":"Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients.","volume":"22","author":"Willis","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00228-001-0389-2","article-title":"Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy.","volume":"57","author":"Le Guellec","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/FTD.0b013e3181559f8a","article-title":"Evaluation of the practicability of limited sampling strategies for the estimation of mycophenolic acid exposure in Chinese adult renal recipients.","volume":"29","author":"Zicheng","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","article-title":"Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.","volume":"27","author":"Pr\u00e9maud","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","article-title":"A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.","volume":"44","author":"Pr\u00e9maud","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.transproceed.2004.12.188","article-title":"Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: A cost effective strategy for reducing acute rejection.","volume":"37","author":"Balshaw","year":"2005","journal-title":"Transplant Proc"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00019053-200422100-00001","article-title":"An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.","volume":"22","author":"Keown","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.transproceed.2004.09.016","article-title":"C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.","volume":"37","author":"Dominquez","year":"2005","journal-title":"Transplant Proc"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/lt.21355","article-title":"A randomized, prospective, pharmacoeconomic trial of Neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.","volume":"14","author":"Shenoy","year":"2008","journal-title":"Liver Transplant"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","article-title":"Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-contrlled trial.","volume":"27","author":"Van Gelder","year":"2008","journal-title":"Transplantation"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.phrs.2009.09.006","article-title":"Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients.","volume":"61","author":"Pr\u00e9maud","year":"2010","journal-title":"Pharmacol Res"},{"key":"R26-12-20210129","first-page":"580","article-title":"Tacrolimus versus cyclosporine in renal transplantation in Italy: Cost-minimisation and cost-effectiveness analyses.","volume":"15","author":"Lazzaro","year":"2002","journal-title":"J Nephrol"},{"key":"R27-12-20210129","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1016\/j.transproceed.2007.09.009","article-title":"Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.","volume":"39","author":"Annemans","year":"2007","journal-title":"Transplant Proc"},{"key":"R29-12-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10754-007-9025-8","article-title":"International study of health care organization and financing for end-stage renal disease in France.","volume":"7","author":"Durand-Zaleski","year":"2007","journal-title":"Int J Health Care Finance Econ"},{"key":"R30-12-20210129","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"R31-12-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003088-199834040-00001","article-title":"Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?","volume":"34","author":"Ensom","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R32-12-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Cost-effectiveness of therapeutic drug monitoring: A systematic review.","volume":"27","author":"Touw","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R33-12-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00042560-200007010-00005","article-title":"Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.","volume":"24","author":"Chaix","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R34-12-20210129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00019053-200220100-00004","article-title":"Mycophenolate mofetil. A pharmacoeconomic review of its use in solid organ transplantation.","volume":"20","author":"Young","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"R35-12-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1524-4733.2007.00249.x","article-title":"Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer.","volume":"11","author":"Bonastre","year":"2008","journal-title":"Value Health"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0b013e3181d75952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:15:49Z","timestamp":1786040149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201005270-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,27]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181d75952","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5,27]]}}}